Identification

Name
Prasterone sulfate
Accession Number
DB05804
Type
Small Molecule
Groups
Investigational
Description

DHEA sulfate is the major steroid of the fetal adrenal. DHEA-S is the principal adrenal androgen and is secreted together with cortisol under the control of ACTH and prolactin. DHEA-S is elevated with hyperprolactinemia.

Structure
Thumb
Synonyms
  • (3-beta)-3-(Sulfooxy)androst-5-en-17-one
  • 17-Ketoandrost-5-en-3beta-yl sulfate
  • 17-oxoandrost-5-en-3β-yl hydrogen sulphate
  • 3-O-Sulfodehydroepiandrosterone
  • 3beta-Hydroxyandrost-5-en-17-one 3-sulfate
  • Androst-5-en-17-on-3beta-yl sulfuric acid
  • Dehydroepiandrosterone 3-sulfate
  • Dehydroepiandrosterone monosulfate
  • Dehydroepiandrosterone sulfate
  • Dehydroepiandrosterone sulphate
  • Dehydroisoandrosterone sulfate
  • Dehydroisoandrosterone-3-sulfate
  • DHEA sulfate
  • DHEA sulphate
  • DHEA-S
  • Prasterone sulphate
International/Other Brands
Inflarest
Categories
UNII
57B09Q7FJR
CAS number
651-48-9
Weight
Average: 368.488
Monoisotopic: 368.165744696
Chemical Formula
C19H28O5S
InChI Key
CZWCKYRVOZZJNM-USOAJAOKSA-N
InChI
InChI=1S/C19H28O5S/c1-18-9-7-13(24-25(21,22)23)11-12(18)3-4-14-15-5-6-17(20)19(15,2)10-8-16(14)18/h3,13-16H,4-11H2,1-2H3,(H,21,22,23)/t13-,14-,15-,16-,18-,19-/m0/s1
IUPAC Name
[(1S,2R,5S,10R,11S,15S)-2,15-dimethyl-14-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-7-en-5-yl]oxidanesulfonic acid
SMILES

Pharmacology

Indication

Investigated for use/treatment in asthma and burns and burn infections.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

The low levels of dehydroepiandrosterone sulfate(DHEA-S)is associated with unfavorable levels of several strong cardiovascular disease risk factors, such as lipids and blood pleasure, which are components of the metabolic syndrome, and insulin levels. DHEA-S deficiency is risk factors of obesity and insulin resistance, but it is not clear, whether this possible influence is independent.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Aromatase deficiencyDisease
17-Beta Hydroxysteroid Dehydrogenase III DeficiencyDisease
Androgen and Estrogen MetabolismMetabolic
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Prasterone sulfate.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Prasterone sulfate.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Prasterone sulfate.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Prasterone sulfate.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Prasterone sulfate.Approved, Withdrawn
AldesleukinPrasterone sulfate may decrease the antineoplastic activities of Aldesleukin.Approved
AlgeldrateThe bioavailability of Prasterone sulfate can be decreased when combined with Algeldrate.Approved, Experimental
AlmagateThe bioavailability of Prasterone sulfate can be decreased when combined with Almagate.Experimental
AlmasilateThe bioavailability of Prasterone sulfate can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Prasterone sulfate.Experimental
AloglutamolThe bioavailability of Prasterone sulfate can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Prasterone sulfate.Experimental
AluminiumThe bioavailability of Prasterone sulfate can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Prasterone sulfate can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Prasterone sulfate can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Prasterone sulfate can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Prasterone sulfate.Approved
AmiodaroneThe serum concentration of Prasterone sulfate can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BPrasterone sulfate may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Prasterone sulfate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Prasterone sulfate.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Prasterone sulfate.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Prasterone sulfate.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Prasterone sulfate.Approved, Investigational
AprepitantThe serum concentration of Prasterone sulfate can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Prasterone sulfate can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Prasterone sulfate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Prasterone sulfate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Prasterone sulfate.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Prasterone sulfate.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Prasterone sulfate.Experimental
BendroflumethiazidePrasterone sulfate may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Prasterone sulfate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Prasterone sulfate.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Prasterone sulfate.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Prasterone sulfate.Experimental
Bismuth SubcitrateThe bioavailability of Prasterone sulfate can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Prasterone sulfate can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Prasterone sulfate can be increased when it is combined with Boceprevir.Approved, Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Prasterone sulfate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Prasterone sulfate.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Prasterone sulfate.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Prasterone sulfate.Experimental
BumetanidePrasterone sulfate may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Prasterone sulfate.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Prasterone sulfate can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Prasterone sulfate can be decreased when combined with Calcium silicate.Experimental
Capromab pendetidePrasterone sulfate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Prasterone sulfate can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Prasterone sulfate.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Prasterone sulfate.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Prasterone sulfate.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Prasterone sulfate.Approved, Investigational
CeritinibPrasterone sulfate may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Prasterone sulfate.Approved, Vet Approved
ChlorothiazidePrasterone sulfate may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Prasterone sulfate can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorthalidonePrasterone sulfate may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Prasterone sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Prasterone sulfate.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Prasterone sulfate can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Prasterone sulfate.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Prasterone sulfate can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Prasterone sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Prasterone sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Prasterone sulfate can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Prasterone sulfate.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Prasterone sulfate.Investigational
CyclopenthiazidePrasterone sulfate may increase the hypokalemic activities of Cyclopenthiazide.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Prasterone sulfate.Investigational
DaidzeinThe serum concentration of Prasterone sulfate can be increased when it is combined with Daidzein.Experimental
DarunavirThe serum concentration of Prasterone sulfate can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Prasterone sulfate.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Prasterone sulfate.Approved, Vet Approved
DienestrolThe serum concentration of Prasterone sulfate can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Prasterone sulfate can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Prasterone sulfate.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prasterone sulfate.Approved
DihydrotestosteronePrasterone sulfate may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DistigmineThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Prasterone sulfate.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Prasterone sulfate.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Prasterone sulfate.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Prasterone sulfate can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Prasterone sulfate can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Prasterone sulfate.Approved
EquolThe serum concentration of Prasterone sulfate can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Prasterone sulfate can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Prasterone sulfate can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Prasterone sulfate can be increased when it is combined with Estrone.Approved
Etacrynic acidPrasterone sulfate may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Prasterone sulfate.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Prasterone sulfate.Experimental
Ethinyl EstradiolThe serum concentration of Prasterone sulfate can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Prasterone sulfate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Prasterone sulfate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Prasterone sulfate.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Prasterone sulfate.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Prasterone sulfate.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Prasterone sulfate.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Prasterone sulfate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Prasterone sulfate.Approved
FenthionThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Prasterone sulfate.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Prasterone sulfate.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Prasterone sulfate.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Prasterone sulfate.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Prasterone sulfate.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Prasterone sulfate.Experimental
FluoxymesteronePrasterone sulfate may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Prasterone sulfate.Approved, Investigational
FosaprepitantThe serum concentration of Prasterone sulfate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Prasterone sulfate can be decreased when it is combined with Fosphenytoin.Approved
FurosemidePrasterone sulfate may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Prasterone sulfate can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Prasterone sulfate is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Ginkgo biloba.Approved, Investigational, Nutraceutical
GLPG-0492Prasterone sulfate may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Prasterone sulfate.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Prasterone sulfate.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Prasterone sulfate.Experimental
HexestrolThe serum concentration of Prasterone sulfate can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Prasterone sulfate.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prasterone sulfate.Approved, Investigational
HydrochlorothiazidePrasterone sulfate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazidePrasterone sulfate may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Prasterone sulfate can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Prasterone sulfate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Prasterone sulfate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Prasterone sulfate.Approved
IdelalisibThe serum concentration of Prasterone sulfate can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Prasterone sulfate.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Prasterone sulfate.Approved
IndapamidePrasterone sulfate may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Prasterone sulfate can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Prasterone sulfate.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Prasterone sulfate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Prasterone sulfate.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Prasterone sulfate is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Prasterone sulfate is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Prasterone sulfate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Prasterone sulfate.Withdrawn
ItraconazoleThe serum concentration of Prasterone sulfate can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Prasterone sulfate.Experimental
KetoconazoleThe serum concentration of Prasterone sulfate can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Prasterone sulfate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Prasterone sulfate.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Prasterone sulfate.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Prasterone sulfate.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Prasterone sulfate.Experimental
LopinavirThe serum concentration of Prasterone sulfate can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Prasterone sulfate.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Prasterone sulfate.Approved, Investigational
LumacaftorThe serum concentration of Prasterone sulfate can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Prasterone sulfate.Approved, Investigational
MagaldrateThe bioavailability of Prasterone sulfate can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Prasterone sulfate can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Prasterone sulfate can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Prasterone sulfate can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Prasterone sulfate.Approved
Magnesium silicateThe bioavailability of Prasterone sulfate can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Prasterone sulfate can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Prasterone sulfate.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prasterone sulfate.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Prasterone sulfate.Approved
MefloquineThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Prasterone sulfate.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Prasterone sulfate.Approved
MesterolonePrasterone sulfate may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Prasterone sulfate can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Prasterone sulfate.Investigational, Withdrawn
MethallenestrilThe serum concentration of Prasterone sulfate can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazidePrasterone sulfate may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Methyl salicylate.Approved, Vet Approved
MethyltestosteronePrasterone sulfate may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Metoclopramide.Approved, Investigational
MetolazonePrasterone sulfate may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Prasterone sulfate can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Minaprine.Approved
MitotaneThe serum concentration of Prasterone sulfate can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Prasterone sulfate.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Prasterone sulfate.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Prasterone sulfate.Experimental
MoxestrolThe serum concentration of Prasterone sulfate can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Prasterone sulfate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prasterone sulfate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Prasterone sulfate.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Prasterone sulfate.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Prasterone sulfate.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Nalidixic Acid.Approved, Investigational
NandrolonePrasterone sulfate may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Prasterone sulfate.Approved, Vet Approved
NefazodoneThe serum concentration of Prasterone sulfate can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Prasterone sulfate can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Prasterone sulfate.Approved
NevirapineThe serum concentration of Prasterone sulfate can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Prasterone sulfate.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Prasterone sulfate.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Prasterone sulfate.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Prasterone sulfate.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prasterone sulfate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Prasterone sulfate.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Prasterone sulfate.Vet Approved
OxandrolonePrasterone sulfate may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Prasterone sulfate.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Oxolinic acid.Experimental
OxymetholonePrasterone sulfate may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Prasterone sulfate.Approved, Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Prasterone sulfate.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Prasterone sulfate.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Prasterone sulfate can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Prasterone sulfate can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Prasterone sulfate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Prasterone sulfate.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Prasterone sulfate.Approved, Investigational
PhenytoinThe serum concentration of Prasterone sulfate can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prasterone sulfate.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Pipemidic acid.Experimental
PiretanidePrasterone sulfate may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Prasterone sulfate.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Prasterone sulfate.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Prasterone sulfate.Experimental
Polyestradiol phosphateThe serum concentration of Prasterone sulfate can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazidePrasterone sulfate may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Prasterone sulfate can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Prasterone sulfate.Experimental, Investigational
PrimidoneThe serum concentration of Prasterone sulfate can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Prasterone sulfate.Experimental
PromestrieneThe serum concentration of Prasterone sulfate can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Prasterone sulfate.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Prasterone sulfate.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Prasterone sulfate.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Prasterone sulfate.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Prasterone sulfate can be increased when it is combined with Quinestrol.Approved
QuinethazonePrasterone sulfate may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Rabies virus inactivated antigen, A.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Prasterone sulfate.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Prasterone sulfate.Approved, Experimental, Investigational
RifabutinThe serum concentration of Prasterone sulfate can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Prasterone sulfate can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Prasterone sulfate can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Rindopepimut.Investigational
RitonavirThe serum concentration of Prasterone sulfate can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Prasterone sulfate.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Prasterone sulfate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Prasterone sulfate.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Prasterone sulfate.Approved
SaquinavirThe serum concentration of Prasterone sulfate can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Prasterone sulfate can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Prasterone sulfate.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Prasterone sulfate.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Prasterone sulfate.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Sitafloxacin.Experimental, Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Prasterone sulfate is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Prasterone sulfate.Investigational
St. John's WortThe serum concentration of Prasterone sulfate can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanozololPrasterone sulfate may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Prasterone sulfate can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Prasterone sulfate.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Prasterone sulfate.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Prasterone sulfate.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Prasterone sulfate.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Prasterone sulfate can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Prasterone sulfate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Tacrine.Investigational, Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Prasterone sulfate.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Prasterone sulfate.Approved, Withdrawn
TelithromycinThe serum concentration of Prasterone sulfate can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Prasterone sulfate.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Prasterone sulfate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Prasterone sulfate.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Prasterone sulfate.Approved
TestosteronePrasterone sulfate may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Prasterone sulfate is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Prasterone sulfate.Approved
TiboloneThe serum concentration of Prasterone sulfate can be increased when it is combined with Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Prasterone sulfate.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Prasterone sulfate.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Prasterone sulfate.Approved
TorasemidePrasterone sulfate may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Prasterone sulfate.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Prasterone sulfate.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Trichlorfon.Vet Approved
TrichlormethiazidePrasterone sulfate may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Prasterone sulfate.Investigational
TrovafloxacinThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Prasterone sulfate.Investigational, Withdrawn
VoriconazoleThe serum concentration of Prasterone sulfate can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinPrasterone sulfate may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prasterone sulfate.Approved, Investigational
ZeranolThe serum concentration of Prasterone sulfate can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Prasterone sulfate.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Prasterone sulfate.Withdrawn
Zoster vaccineThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Zoster vaccine.Approved
Food Interactions
Not Available

References

General References
  1. Altman R, Motton DD, Kota RS, Rutledge JC: Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells: roles of PPARalpha and NF-kappaB. Vascul Pharmacol. 2008 Feb-Mar;48(2-3):76-84. doi: 10.1016/j.vph.2007.12.002. Epub 2007 Dec 15. [PubMed:18255343]
  2. Rabijewski M, Papierska L, Kozakowski J, Zgliczynski W: [The relationship between androgens concentrations (testosterone and dehydroepiandrosterone sulfate) and metabolic syndrome in non-obese elderly men]. Endokrynol Pol. 2007 Nov-Dec;58(6):496-504. [PubMed:18205106]
  3. Geyer J, Doring B, Meerkamp K, Ugele B, Bakhiya N, Fernandes CF, Godoy JR, Glatt H, Petzinger E: Cloning and functional characterization of human sodium-dependent organic anion transporter (SLC10A6). J Biol Chem. 2007 Jul 6;282(27):19728-41. Epub 2007 May 9. [PubMed:17491011]
External Links
Human Metabolome Database
HMDB01032
KEGG Compound
C04555
PubChem Compound
12594
PubChem Substance
175427036
ChemSpider
12074
BindingDB
50375559
ChEBI
16814
ChEMBL
CHEMBL259898
Wikipedia
Dehydroepiandrosterone_sulfate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2, 3CompletedTreatmentMinor burns1
3SuspendedTreatmentPlasmodium Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00806 mg/mLALOGPS
logP0.49ALOGPS
logP3.42ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)-1.4ChemAxon
pKa (Strongest Basic)-7.5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area80.67 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity94.65 m3·mol-1ChemAxon
Polarizability39.86 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.996
Blood Brain Barrier+0.9388
Caco-2 permeable-0.6601
P-glycoprotein substrateNon-substrate0.507
P-glycoprotein inhibitor IInhibitor0.6926
P-glycoprotein inhibitor IINon-inhibitor0.9548
Renal organic cation transporterNon-inhibitor0.7909
CYP450 2C9 substrateNon-substrate0.8322
CYP450 2D6 substrateNon-substrate0.8338
CYP450 3A4 substrateSubstrate0.6799
CYP450 1A2 substrateNon-inhibitor0.8203
CYP450 2C9 inhibitorNon-inhibitor0.84
CYP450 2D6 inhibitorNon-inhibitor0.882
CYP450 2C19 inhibitorNon-inhibitor0.8117
CYP450 3A4 inhibitorNon-inhibitor0.9481
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7575
Ames testNon AMES toxic0.5802
CarcinogenicityNon-carcinogens0.586
BiodegradationNot ready biodegradable0.9519
Rat acute toxicity2.4168 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5859
hERG inhibition (predictor II)Inhibitor0.5409
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as sulfated steroids. These are sterol lipids containing a sulfate group attached to the steroid skeleton.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Sulfated steroids
Direct Parent
Sulfated steroids
Alternative Parents
Androstane steroids / 17-oxosteroids / Delta-5-steroids / Sulfuric acid monoesters / Alkyl sulfates / Ketones / Organic oxides / Hydrocarbon derivatives
Substituents
Sulfated steroid skeleton / Androstane-skeleton / 17-oxosteroid / Oxosteroid / Delta-5-steroid / Sulfuric acid ester / Alkyl sulfate / Sulfuric acid monoester / Sulfate-ester / Organic sulfuric acid or derivatives
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
steroid sulfate, 17-oxo steroid (CHEBI:16814) / sulfates, C19 steroids (androgens) and derivatives, Androgens (C04555) / Sulfates (LMST05020010)

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name
CYP19A1
Uniprot ID
P11511
Uniprot Name
Aromatase
Molecular Weight
57882.48 Da
References
  1. Jones ME, Boon WC, McInnes K, Maffei L, Carani C, Simpson ER: Recognizing rare disorders: aromatase deficiency. Nat Clin Pract Endocrinol Metab. 2007 May;3(5):414-21. [PubMed:17452968]
  2. ElBeltagy K, Honda K, Ozaki K, Misugi T, Tokuyama O, Kimura M, Kira Y, Ishiko O: In vitro effect of dehydroepiandrosterone sulfate on steroid receptors, aromatase, cyclooxygenase-2 expression, and steroid hormone production in preovulatory human granulosa cells. Fertil Steril. 2007 Oct;88(4 Suppl):1135-42. Epub 2007 Jun 4. [PubMed:17548088]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Bacsi K, Kosa JP, Borgulya G, Balla B, Lazary A, Nagy Z, Horvath C, Speer G, Lakatos P: CYP3A7*1C polymorphism, serum dehydroepiandrosterone sulfate level, and bone mineral density in postmenopausal women. Calcif Tissue Int. 2007 Mar;80(3):154-9. Epub 2007 Mar 3. [PubMed:17334880]
  2. Smit P, van Schaik RH, van der Werf M, van den Beld AW, Koper JW, Lindemans J, Pols HA, Brinkmann AO, de Jong FH, Lamberts SW: A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels. J Clin Endocrinol Metab. 2005 Sep;90(9):5313-6. Epub 2005 Jun 28. [PubMed:15985487]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. ElBeltagy K, Honda K, Ozaki K, Misugi T, Tokuyama O, Kimura M, Kira Y, Ishiko O: In vitro effect of dehydroepiandrosterone sulfate on steroid receptors, aromatase, cyclooxygenase-2 expression, and steroid hormone production in preovulatory human granulosa cells. Fertil Steril. 2007 Oct;88(4 Suppl):1135-42. Epub 2007 Jun 4. [PubMed:17548088]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-dependent organic anion transmembrane transporter activity
Specific Function
Transports sulfoconjugated steroid hormones, as well as taurolithocholic acid-3-sulfate and sulfoconjugated pyrenes in a sodium-dependent manner.
Gene Name
SLC10A6
Uniprot ID
Q3KNW5
Uniprot Name
Solute carrier family 10 member 6
Molecular Weight
41258.24 Da
References
  1. Geyer J, Doring B, Meerkamp K, Ugele B, Bakhiya N, Fernandes CF, Godoy JR, Glatt H, Petzinger E: Cloning and functional characterization of human sodium-dependent organic anion transporter (SLC10A6). J Biol Chem. 2007 Jul 6;282(27):19728-41. Epub 2007 May 9. [PubMed:17491011]

Drug created on November 18, 2007 11:27 / Updated on November 09, 2017 03:52